Artiva biotherapeutics (nas: artv)
Artiva Biotherapeutics (NAS: ARTV) is a biopharmaceutical company focused on developing off-the-shelf, allogeneic NK cell therapies for treating hematologic malignancies and solid tumors.
Artiva biotherapeutics (nas: artv) Overview
Artiva biotherapeutics (nas: artv) Funding Rounds
Round | Date | Amount Raised | Valuation | Investors | Sources |
---|---|---|---|---|---|
IPO | 7/15/2021 | ||||
Series B | 2/26/2021 | ||||
Series A | 6/26/2020 |
Artiva biotherapeutics (nas: artv) 409a Valuations
Date | Price per share | Est. Valuation | Filling |
---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Artiva biotherapeutics (nas: artv) Filings
Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Latest Artiva biotherapeutics (nas: artv) News
Positive Buy Rating for Artiva Biotherapeutics, Inc. Driven by Promising AlloNK Cell Therapy Developments
TipRanksAugust 7, 2025
Artiva Biotherapeutics: Analyst Maintains Buy Rating Amid Promising AlloNK Cell Therapy Developments
AInvestAugust 7, 2025
Artiva Biotherapeutics Raises $300M Through Mixed Securities Shelf Offering
AInvestAugust 7, 2025
Buy Rating Affirmed for Artiva Biotherapeutics Amid Promising AlloNK Data and Strong Financial Position
TipRanksAugust 7, 2025
Artiva Biotherapeutics Reports Q2 GAAP EPS of -$0.87, Misses Expectations by $0.06; Cash Reserves Expected to Fund Operations into Q2 2027.
AInvestAugust 6, 2025
Artiva Biotherapeutics, Inc.(NasdaqGM: ARTV) dropped from Russell Microcap Growth Index
MarketScreenerJune 30, 2025
Artiva Biotherapeutics, Inc.(NasdaqGM: ARTV) dropped from Russell 2000 Growth Index
MarketScreenerJune 30, 2025